Leung Janni, Lim Carmen C W, Chiu Vivian, Chung Jack, Mekonen Tesfa, Dawson Danielle, Hall Wayne D, Chan Gary C K
National Centre for Youth Substance Use Research, The University of Queensland, Australia.
School of Psychology, The University of Queensland, Australia.
Addict Behav Rep. 2022 May 26;15:100436. doi: 10.1016/j.abrep.2022.100436. eCollection 2022 Jun.
It is important to know the prevalence and source of medicinal cannabis use in the population because non-prescribed medicinal use of cannabis products places individuals at higher risk of harms. We estimated the prevalence and correlates of the use of cannabis for medicinal purposes in Australia, three years after Australians were given legal access.
Cross-sectional.
The 2019 Australian National Drug Strategy Household Survey.
Participants were 22,015 Australians aged 14 or above.
Self-reported cannabis use in the last 12 months for medicinal purposes only, both medicinal/recreational reasons, or recreationally only. Those who reported medicinal use were asked if it had been prescribed by a doctor. Prevalence estimates were weighted to the population and multinomial logistic regression examined the correlates.
The prevalence of any medicinal cannabis use in the past year was 2.6%. Only 0.8% of the sample reported using cannabis solely for medicinal reasons, 95.9% of whom did not have a prescription. A self-reported diagnosis of cancer was associated with medicinal use only. Self-reported chronic pain was associated with both medicinal only and medicinal/recreational use. Medicinal cannabis use was associated with opioids use.
In 2019, the prevalence of cannabis use solely for medicinal reasons remains under 1%, was more common among people with specific medical conditions, but most individuals do not have a prescription. The prevalence of self-reported medicinal cannabis use in Australia is low and there is limited use of the legal pathway for medicinal cannabis.
了解人群中药用大麻的使用流行情况和来源很重要，因为非处方使用大麻产品会使个人面临更高的伤害风险。在澳大利亚人获得合法使用大麻三年后，我们估计了澳大利亚药用大麻的使用流行情况及其相关因素。
横断面研究。
2019年澳大利亚国家毒品战略家庭调查。
22015名14岁及以上的澳大利亚人。
仅报告过去12个月出于药用目的使用大麻的情况，出于药用/娱乐原因使用大麻的情况，或仅出于娱乐目的使用大麻的情况。报告使用大麻用于药用的人被问及是否有医生开具的处方。流行率估计值根据总体情况进行加权，并通过多项逻辑回归分析相关因素。
过去一年中任何药用大麻的使用流行率为2.6%。只有0.8%的样本报告仅出于药用原因使用大麻，其中95.9%的人没有处方。自我报告患有癌症与仅药用大麻使用相关。自我报告的慢性疼痛与仅药用和药用/娱乐性使用均相关。药用大麻使用与阿片类药物使用相关。
2019年，仅出于药用原因使用大麻的流行率仍低于1%，在患有特定疾病的人群中更为常见，但大多数人没有处方。澳大利亚自我报告的药用大麻使用流行率较低，药用大麻合法途径的使用有限。
